Journal of Infection and Chemotherapy最新文献

{"title":"Isepamicin alone as antimicrobial prophylaxis for transrectal prostate needle biopsy: “Do we still need levofloxacin? ”","authors":"Hiroki Yamada ,&nbsp;Kojiro Tashiro ,&nbsp;Yusuke Takahashi ,&nbsp;Mariko Honda ,&nbsp;Hajime Ohnuma ,&nbsp;Keiji Yasue ,&nbsp;Mahito Atsuta ,&nbsp;Kei-Ichiro Miyajima ,&nbsp;Mimu Ishikawa ,&nbsp;Yuki Takiguchi ,&nbsp;Hiroshi Kiyota ,&nbsp;Takahiro Kimura","doi":"10.1016/j.jiac.2025.102645","DOIUrl":"10.1016/j.jiac.2025.102645","url":null,"abstract":"<div><div>The purpose of this study was to investigate whether conventional levofloxacin (LVFX) administration is unnecessary for transrectal ultrasound-guided prostate needle biopsy (TRP-Bx) in view of the increase in LVFX-resistant <em>Escherichia coli</em> and appropriate use of antibiotics. The study included 636 cases undergoing TRP-Bx, divided into two groups based on the prophylactic antibiotic regimen. Group 1 (n = 308) received both oral levofloxacin (LVFX) 500 mg and intravenous isepamicin (ISP) 400 mg. Group 2 (n = 328) received only intravenous ISP 400 mg. Biopsies involved sampling 12 cores using an 18G needle. A high-risk subgroup included patients with a large prostate (&gt;75 ml), severe dysuria, diabetes mellitus, or steroid use. Significantly more high-risk cases were in Group 2 than in Group 1 (35.7 % vs. 24.4 %, p = 0.003). Febrile genitourinary tract infections (fGUTIs) occurred in three patients (0.5 %), with no significant difference between the groups (0.3 % in Group 1 vs. 0.6 % in Group 2). No fGUTI complications were noted among high-risk cases in either group. Of the fGUTI cases, one involved LVFX-resistant <em>E. coli;</em> another involved <em>E. coli</em> susceptible to both LVFX and amikacin, isolated from blood. The single- and short-duration intravenous dose of ISP 400 mg would appear to be one of possible options in preventing TRP-Bx-related fGUTIs in both low-risk and high-risk patients.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102645"},"PeriodicalIF":1.9,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Days of antibiotic spectrum coverage (DASC) as predictors of recurrent Clostridioides difficile infection: A retrospective cohort study","authors":"Nobuaki Mori ,&nbsp;Yuichi Shibata ,&nbsp;Jun Hirai ,&nbsp;Nobuhiro Asai ,&nbsp;Hiroshige Mikamo","doi":"10.1016/j.jiac.2025.102650","DOIUrl":"10.1016/j.jiac.2025.102650","url":null,"abstract":"<div><h3>Background</h3><div>Broad-spectrum antibiotic use increases the risk of <em>Clostridioides difficile</em> infection (CDI), with recurrence rates varying by antibiotic type, spectrum, and treatment duration. We assessed CDI recurrence risk using the days of antibiotic spectrum coverage (DASC) score, considering antibiotic spectrum and use duration.</div></div><div><h3>Methods</h3><div>We retrospectively analyzed patients with hospital-acquired CDI. A logistic regression analysis was used to evaluate CDI recurrence, incorporating three variables: DASC score prior to CDI diagnosis, type of anti-CDI drugs, or DASC score after CDI diagnosis.</div></div><div><h3>Results</h3><div>Overall, 246 patients were included, with 31 (12.6 %) cases of recurrence. Median DASC scores within 30 days prior to CDI diagnosis were higher in the recurrent group than in the non-recurrent group (128 [interquartile range: 106–217] vs. 80 [interquartile range: 39–142], p &lt; 0.01). Using the lowest quartile of DASC scores as the reference, the analysis indicated higher relative risks of CDI recurrence in the upper quartiles. However, daily DASC scores post-CDI diagnosis did not correlate with recurrence. Compared to metronidazole, fidaxomicin lowered the risk of CDI recurrence (relative risk 0.2, 95 % confidence interval: 0.1–0.8, p = 0.03).</div></div><div><h3>Conclusions</h3><div>The DASC score within 30 days prior to CDI diagnosis appears to be a predictive risk factor for CDI recurrence.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102650"},"PeriodicalIF":1.9,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143365108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"First reported case of disseminated Cunninghamella phaeospora infection with multidrug resistance in acute myeloid leukemia","authors":"Tomohito Shimada ,&nbsp;Akira Watanabe ,&nbsp;Kaori Akita ,&nbsp;Kana Bando ,&nbsp;Atsushi Takahata ,&nbsp;Kazuhiro Ishikawa ,&nbsp;Shigeo Toyota","doi":"10.1016/j.jiac.2025.102646","DOIUrl":"10.1016/j.jiac.2025.102646","url":null,"abstract":"<div><div>Mucormycosis is a severe mold infection primarily affecting immunocompromised patients. Neutropenia, steroid use, hyperglycemia, and diabetes are recognized as significant risk factors. <em>Cunninghamella</em> species are rare pathogenic fungi associated with high mortality rates and multidrug resistance. However, there have been no reports of <em>C. phaeospora</em> being identified as the causative agent of clinical infection. We report a case of a 71-year-old man who developed right middle lobe pneumonia during salvage induction therapy for relapsed acute myeloid leukemia. Based on the clinical course, mucormycosis was suspected, and antifungal therapy was initiated with isavuconazole (200 mg every 8 hours for six doses, followed by 200 mg daily) and later switched to liposomal amphotericin B (5 mg/kg/day). Despite these interventions, the patient's respiratory failure progressed, culminating in a fatal hemorrhagic infarction of the right lung. An autopsy revealed invasive fungal involvement in multiple organs, including the lungs and liver. Genetic identification of the isolated fungi demonstrated <em>C. phaeospora</em>, confirming disseminated <em>C. phaeospora</em> infection. Susceptibility testing showed high Minimum Inhibition Concentrations/Minimum Effective Concentrations to all tested antifungal agents. This is the first reported case of disseminated infection caused by <em>C. phaeospora</em> with multidrug resistance. This case highlights the diagnostic and therapeutic challenges associated with rare pathogenic fungi. It underscores the importance of early identification of Mucorales, including susceptibility testing, to optimize antifungal therapy and consider appropriate surgical interventions. Further research is required to elucidate the mechanisms of antifungal resistance and clinical characteristics of <em>C. phaeospora</em>.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102646"},"PeriodicalIF":1.9,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of transurethral enucleation with bipolar for benign prostatic hyperplasia patients with chronic prostatitis/chronic pelvic pain syndrome – Single center retrospective study","authors":"Yoshikazu Togo,&nbsp;Shimpei Yoshioka,&nbsp;Yohei Kaizuka,&nbsp;Seiji Nagasawa","doi":"10.1016/j.jiac.2025.102647","DOIUrl":"10.1016/j.jiac.2025.102647","url":null,"abstract":"<div><h3>Introduction</h3><div>Transurethral prostate surgery is the standard procedure for patients with benign prostatic hyperplasia (BPH), while the efficacy of surgical treatment for patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) remains unclear. This study was conducted to evaluate the usefulness of transurethral enucleation with bipolar (TUEB) of the prostate for BPH patients with CP/CPPS.</div></div><div><h3>Methods</h3><div>Between February 2018 and May 2024, 53 BPH patients with CP/CPPS underwent TUEB of the prostate at our institution and were followed for more than three months. Changes in the National Institutes of Health chronic prostatitis symptom index (NIH-CPSI) score before and after surgery were retrospectively examined. Patients with bladder stones or indwelling urethral catheters before surgery were excluded.</div></div><div><h3>Results</h3><div>Mean values for NIH-CPSI total, pain domain, urinary symptoms domain, and quality of life impact domain scores at the baseline were 21.7, 7.0, 6.4, and 8.3, respectively. Follow-up examinations showed scores of 11.1, 2.5, 3.3, and 5.3, respectively, after one month, 7.9, 1.3, 2.9, and 3.6, respectively, after three months, 4.8, 0.5, 1.7, and 2.5, respectively, after six months, and 4.5, 0.6, 1.7, and 2.3, respectively, after 12 months, with all domain scores significantly reduced as compared with the baseline (P &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>The present results suggest that TUEB of the prostate is effective for alleviating not only urinary symptoms but also pain in BPH patients with CP/CPPS.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102647"},"PeriodicalIF":1.9,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143350293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of fosfomycin susceptibility testing methods: A focus on multidrug-resistant Klebsiella pneumoniae using ECOFF values","authors":"Zeycan Semerci ,&nbsp;Fatih Mehmet Akıllı ,&nbsp;Arzu İlki","doi":"10.1016/j.jiac.2025.102643","DOIUrl":"10.1016/j.jiac.2025.102643","url":null,"abstract":"<div><h3>Introduction</h3><div>We aimed to evaluate the performance of two methods; disc diffusion and gradient test with the gold standard agar dilution method in determining the susceptibility of fosfomycin, in multidrug-resistant (MDR) <em>K. pneumoniae</em> isolates causing urinary tract infections.</div></div><div><h3>Methods</h3><div><em>K. pneumoniae</em> producing carbapenemase and extended-spectrum beta-lactamase (ESBL) isolated from urine samples submitted to the clinical microbiology laboratory were included in the study. The isolates were tested using gradient test (MTS, Liofilchem, Italy) and disc diffusion (Oxoid, UK). Agar dilution was employed as the reference method. Since there is no MIC value for <em>K. pneumoniae</em> in EUCAST, epidemiological cut-off values (ECOFFs) were determined and susceptibility and error rates were calculated.</div></div><div><h3>Results</h3><div>In this study, among the 251 ESBL-positive <em>K. pneumoniae</em> isolates, 20(8 %) were also positive for carbapenemase. The ECOFF was determined as 128 mg/L for <em>K. pneumoniae</em>. When all study isolates (n:251) were considered, 87.6%(220/251) were wild-type (WT) for fosfomycin (MIC≤128 mg/L). Among ESBL-positive but carbapenemase-negative isolates (n:231), 87.8%(203/231) were WT for fosfomycin, and among ESBL and carbapenemase-positive isolates (n:20), 85.0%(17/20) were WT. The MIC_50/90 values were determined to be 8/256 mg/L. When compared to agar dilution, the categorical agreement was 96.8% for the gradient test and 94.8 % for disc diffusion. While the gradient test showed a 16.1% very major error (VME) rate with no major errors (ME), disk diffusion revealed 35.4 % VME rate and 5.8 % ME rate.</div></div><div><h3>Conclusion</h3><div>A significant proportion of ESBL-positive <em>K. pneumoniae</em> isolates were WT for fosfomycin. The gradient test with 96.8% categorical agreement appears to be a good alternative, but agar dilution remains the gold Standard for reference laboratories.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102643"},"PeriodicalIF":1.9,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143350292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fully automated identification of Neisseria meningitidis using the BD MAX system in a clinical laboratory setting: A preliminary study","authors":"Rika Inose ,&nbsp;Yoshifumi Uwamino ,&nbsp;Wataru Aoki ,&nbsp;Yuka Kamoshita ,&nbsp;Mika Nagata ,&nbsp;Osamu Ishihara ,&nbsp;Hiromitsu Yokota ,&nbsp;Hiromichi Matsushita","doi":"10.1016/j.jiac.2025.102648","DOIUrl":"10.1016/j.jiac.2025.102648","url":null,"abstract":"<div><div>The rapid and accurate identification of <em>Neisseria meningitidis</em>, a pathogen that causes invasive infections and meningitis, is crucial for its effective clinical management and infection control. However, identification using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry may misidentify other <em>Neisseria</em> species as <em>N. meningitidis</em>, thus necessitating confirmatory tests based on biochemical properties. These tests require high bacterial concentrations that are achieved through subculturing, which can increase biosafety risks in laboratories.</div><div>In this study, we developed a real-time polymerase chain reaction detection system for <em>N. meningitidis</em> using the BD MAX automated genetic testing platform. We then evaluated its accuracy using 25 strains of clinically isolated <em>Neisseria</em> species, including <em>N. meningitidis</em>. Our detection results were in full agreement with those of sequencing-based identification, with a minimum detection sensitivity of 10 CFU/mL. The BD MAX system completes all measurements in a closed system, allowing for the rapid and precise identification of <em>N. meningitidis</em> while reducing laboratory biosafety risks.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 4","pages":"Article 102648"},"PeriodicalIF":1.9,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143255815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Culture-negative infective endocarditis due to Neisseria bacilliformis identified via 16S rRNA gene analysis from resected valve tissue: Case report and review of the literature","authors":"Yoshinori Takahashi ,&nbsp;Junya Nakade ,&nbsp;Yoshitaka Zaimoku ,&nbsp;Naoki Watanabe ,&nbsp;Tomohisa Watari ,&nbsp;Yoshihito Otsuka ,&nbsp;Yasunori Iwata ,&nbsp;Hajime Kanamori","doi":"10.1016/j.jiac.2024.08.017","DOIUrl":"10.1016/j.jiac.2024.08.017","url":null,"abstract":"<div><div>Blood culture-negative infective endocarditis (BCNE) has a poorer prognosis than culture-positive cases. Thus, it is crucial to determine the pathogenic microorganism using molecular diagnostic techniques, in addition to conventional techniques, including cultures of blood and/or resected valve tissue. Herein, we report a case of culture-negative infective endocarditis (IE) caused by <em>Neisseria bacilliformis</em>, as identified by 16S rRNA analysis of valve tissue. <em>N. bacilliformis</em> a non-gonococcal and non-meningococcal <em>Neisseria</em> species that partially comprises the oropharyngeal microbiome, and reports of invasive infections have increased recently. We conducted a literature review of IE caused by <em>N. bacilliformis</em> and found that beta-lactam antibiotics were effective with a relatively favorable prognosis. To the best of our knowledge, this is the first case of culture-negative IE in which <em>N. bacilliformis</em> was identified via 16S rRNA analysis.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 2","pages":"Article 102502"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Descriptive analysis of safety and immunogenicity profiles of a 15-valent pneumococcal conjugate vaccine between subcutaneous and intramuscular administration in a phase 1 study of healthy Japanese infants (V114-028)","authors":"Keiko Wan,&nbsp;Masayoshi Shirakawa,&nbsp;Miyuki Sawata","doi":"10.1016/j.jiac.2024.10.007","DOIUrl":"10.1016/j.jiac.2024.10.007","url":null,"abstract":"<div><h3>Introduction</h3><div>Subcutaneous (SC) administration is typically used for pediatric inactivated vaccines in Japan, whereas intramuscular (IM) administration is used outside Japan. We previously reported the safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine (PCV), administered subcutaneously and intramuscularly in a Japanese phase 1 study (V114-028). Here, we report secondary descriptive analyses on V114 groups of the study to further assess the safety and immunogenicity profiles of V114 between the administration routes.</div></div><div><h3>Methods</h3><div>A total of 133 healthy Japanese infants were randomized to receive V114-SC (n = 44), V114-IM (n = 45), or PCV13-SC (n = 44) at approximately 3, 4, 5, and 12–15 months of age. Adverse events (AEs) from Days 1–14 post-vaccination and vaccine-related serious AEs from Day 1 to 1-month post-dose 4 were reported. Serotype-specific immunoglobulin G (IgG) responses were measured across the vaccination series.</div></div><div><h3>Results</h3><div>Proportions of participants with solicited systemic AEs (irritability, somnolence, decreased appetite, and urticaria) and pyrexia were generally comparable between the groups. Compared with V114-SC, patients receiving V114-IM had a lower incidence of irritability and somnolence, and higher incidence of decreased appetite. Proportion of participants with solicited injection-site erythema was lower with V114-IM (82.2%) than V114-SC (100.0%). Those with other solicited injection-site AEs (induration, swelling, and pain) were generally comparable between the groups, with lower observed proportions with V114-IM. Serotype-specific IgG responses were also generally comparable between the groups, including at pre-toddler dose.</div></div><div><h3>Conclusions</h3><div>These results suggest the utility of IM administration as an option for V114 vaccination in Japanese infants.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 2","pages":"Article 102539"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142391063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High plasma concentration of tenofovir alafenamide in people living with HIV with ABCB1 genetic variants","authors":"Kiyoto Tsuchiya ,&nbsp;Hieu Trung Tran ,&nbsp;Akira Kawashima ,&nbsp;Koji Watanabe ,&nbsp;Akinobu Hamada ,&nbsp;Shinichi Oka ,&nbsp;Hiroyuki Gatanaga","doi":"10.1016/j.jiac.2024.10.009","DOIUrl":"10.1016/j.jiac.2024.10.009","url":null,"abstract":"<div><h3>Objectives</h3><div>We aimed to analyze the relationships between single nucleotide polymorphisms in the ATP-binding cassette transporter B1 (ABCB1) and G2 (ABCG2) genes and plasma concentrations of tenofovir alafenamide (TAF), tenofovir (TFV), and emtricitabine (FTC).</div></div><div><h3>Methods</h3><div>We recruited 10 people living with HIV receiving once-daily treatment with a single tablet containing TAF (25 mg), FTC (200 mg), and bictegravir (50 mg). Peripheral blood samples were collected at 0, 1, 2, 3, 4, 6, 8, 12, and 24 h after administration. Plasma concentrations of TAF, TFV, and FTC were quantified using liquid chromatography-tandem mass spectrometry. Genotyping for allelic variants of ABCB1, including 1236C &gt; T (rs1128503), 2677 G &gt; T/A (rs2032582), 3435C &gt; T (rs1045642), 4036 A &gt; G (rs3842) and ABCG2 421C &gt; A (rs2231142), was performed using TaqMan Drug Metabolism Assays.</div></div><div><h3>Results</h3><div>None of the genotypes for ABCB1 1236C &gt; T, 2677 G &gt; T/A, 3435C &gt; T, and ABCG2 421C &gt; A exhibited correlations with plasma concentrations of TAF, TFV, and FTC. In contrast, individuals with the ABCB1 4036 AG genotype (188.7 ng/mL, n = 3) exhibited a significantly higher mean peak plasma concentration of TAF than those with the ABCB1 4036 AA genotype (67.7 ng/mL, n = 7) (<em>p</em> = 0.0167). However, these genotypes did not affect the elimination of terminal half-lives of TAF.</div></div><div><h3>Conclusions</h3><div>The allelic variant ABCB1 4036 A &gt; G is associated with reduced protein expression and function of ABCB1. Individuals with this genetic variant exhibited significantly high peak plasma concentrations of TAF, potentially due to the reduced expression of efflux transporters in the intestines linked to this variant.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 2","pages":"Article 102541"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Symptoms of post COVID-19 condition and diseases/conditions diagnosed after COVID-19 in Japanese patients: A real-world study using a claims database","authors":"Satoshi Kutsuna ,&nbsp;Ryotaro Tajima ,&nbsp;Genta Ito ,&nbsp;Takuji Komeda ,&nbsp;Hideyuki Miyauchi ,&nbsp;Yoshitake Kitanishi","doi":"10.1016/j.jiac.2024.10.008","DOIUrl":"10.1016/j.jiac.2024.10.008","url":null,"abstract":"<div><h3>Background</h3><div>More than 200 symptoms of post coronavirus disease (COVID-19) condition (PCC) impacting patients’ quality of life have been reported. This study describes the symptoms of well-known PCC and diseases/conditions diagnosed after COVID-19 and analyzes the trends in well-known PCC according to the epidemic waves in the Japanese population.</div></div><div><h3>Methods</h3><div>Patients with a COVID-19 diagnosis in the JMDC claims database were matched 1:1 with individuals without COVID-19 diagnosis (controls) based on sex, year and month of birth, and risk factors for aggravation. The first month of COVID-19 diagnosis from January 2020–March 2022 was the index month, and the observation period was from July 2019 to 6 months from the index month (patients) and July 2019–September 2022 (controls).</div></div><div><h3>Results</h3><div>Of 263,456 each of patients and controls after matching, 51.8 % were aged 18–49 years, 56.3 % were male, and 24.5 % had risk factors for aggravation. One in 18 patients experienced well-known PCC 2–3 months after severe acute respiratory syndrome cornonavirus 2 infection, with the highest odds ratio (OR) being for pulmonary thromboembolism (29.37), followed by smell/taste disorder (13.34) and respiratory failure (8.28). Some of the common diseases/conditions diagnosed after COVID-19 comprised those of the genitourinary system, eye and adnexa, and ear and mastoid process and certain infectious and parasitic diseases. Overall, the risk difference decreased from the first to the sixth wave, but the OR was &gt;1.00 for most symptoms even during the sixth wave.</div></div><div><h3>Conclusions</h3><div>PCC symptoms showed a declining trend over time but persisted. Physicians and patients need to recognize PCC symptoms.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 2","pages":"Article 102540"},"PeriodicalIF":1.9,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142467565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}